Background: Patients with polycystic ovary syndrome (PCOS) have an increased prevalence of thrombophilia, leading to higher rates of pregnancy loss. The aim of this study was to determine the association between thrombophilia and recurrent pregnancy loss (RPL) in patients with and without PCOS. Methods: In this comparative caseecontrol study, we included 60 patients with RPL (!3 consecutive pregnancy losses at <20 weeks of gestation) and PCOS (Group 1), 60 patients with PCOS and without RPL (Group 2), 60 patients with RPL and without PCOS (Group 3), and 60 healthy individuals (Group 4). These four study groups were compared regarding serum levels of testosterone, fasting insulin, homocysteine (Hcy), plasminogen activator inhibitor activity (PAI-Fx), protein C, protein S, antithrombin III, activated protein C ratio (APCR), factor V Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase gene mutations. Results: Patients in Group 1 had significantly higher levels of testosterone ( p ¼ 0.026), dehydroepiandrosterone sulfate ( p ¼ 0.035), fasting insulin ( p ¼ 0.015), Hcy ( p ¼ 0.036), and PAI-Fx ( p ¼ 0.008) compared to Group 3. They also had higher proportions of APCR ( p ¼ 0.009) and a higher prevalence of factor V Leiden mutations compared to Group 3 ( p ¼ 0.001). However, there was no significant difference in protein C ( p ¼ 0.088), protein S ( p ¼ 0.514), or antithrombin III ( p ¼ 0.627) between the four study groups. Conclusion: Hyperinsulinemia, hyperandrogenemia, hypofibrinolysis, and hyperhomocysteinemia as well as APCR and factor V Leiden mutations are associated with RPL in patients with PCOS.
Introduction
Polycystic ovary syndrome (PCOS) is one the most common endocrinopathies associated with obesity, oligomenorrhea or amenorrhea, hirsutism, hyperandrogenemia, insulin resistance, and infertility, with an estimated prevalence of 6.5e6.7% in women of reproductive age. 1, 2 PCOS is one of the major causes of infertility worldwide and affects about 20% of infertile couples. 3 Patients with PCOS have an increased risk of first trimester spontaneous abortion ranging from 25% 4 to 73%, 5 which is relatively high. Previous studies have demonstrated that several factors account for this.
Velazquez et al 6 showed that patients with PCOS experience an insulin-induced elevation of plasminogen activator inhibitor activity (PAI-Fx; the most potent inhibitor of fibrinolysis), resulting in hypofibrinolysis and increasing the risk of miscarriage. Thrombophilia is also an important risk factor for abortion in those patients with PCOS. In this regard, previous studies have demonstrated that factor V Leidenassociated thrombophilia, 7, 8 heterozygosity for prothrombin factor mutations, 9 and homozygosity for methylene tetrahydrofolate reductase gene (MTHFR) mutations 10 are other causes of miscarriage in patients with PCOS. In the same way, deficiencies of some proteins, including protein C, protein S, and antithrombin III, are also associated with pregnancy complications and miscarriage. 11 Thrombophilia is a multigenetic disorder due to either acquired coagulation abnormalities (antiphospholipid antibodies) or inherited coagulation abnormalities (deficiencies of the natural anticoagulant proteins antithrombin, protein C or protein S, factor V Leiden, and prothrombin G20210A), or to the metabolic abnormality of hyperhomocysteinemia. 12 In women with recurrent pregnancy loss (RPL), screening reveals a higher than normal incidence of polycystic ovaries. 13 Hence, a high level of fetal loss is characteristic not only of women with RPL with thrombophilia, but also of women with PCOS. It is postulated that the patient's familial thrombophilia, perhaps augmented by the endocrinopathy of PCOS, is associated with failure of embryo transfers and miscarriages. 14 Several studies have investigated the prevalence of socalled mutations and serologic abnormalities of thrombophilia in patients with PCOS, but data regarding the role of these mutations and serologic abnormalities in the pathogenesis of RPL in PCOS patients are still scarce. Thus, we performed this study in order to shed light on the pathogenesis of RPL in patients with PCOS and its association with thrombophilias.
Methods

Study design and subjects
This caseecontrol comparative study was carried out in 2009, at the infertility clinic of Zeinabieh Hospital, a tertiary care center affiliated to the Shiraz University of Medical Sciences. We included four groups of patients in this study. The first group comprised 60 patients with PCOS and RPL (Group 1), while the second group included 60 patients with RPL only (Group 2) selected from those referred to our center for treatment of infertility. The third group was made up of 60 patients with PCOS alone (Group 3), and the fourth group comprised 60 controls (Group 4). Participants in each of the four study groups were matched regarding age, body mass index, and parity. The study was approved by the review board and ethics committee of Shiraz University of Medical Sciences, and informed consent forms were signed by all participants.
RPL was defined as three or more consecutive pregnancy losses at less than 20 weeks of gestation. Pregnant women and those with a history of abortion or major surgery during the previous 5 months, as well as those who had had a recent myocardial infarction, had received aspirin or heparin in the last 15 days, were receiving sex steroid therapy or combined oral contraceptives, or had a history of hematologic, malignant liver, or thromboembolic disease were excluded from the study. Other causes of RPL including chromosomal and uterine abnormalities and antiphospholipid syndrome were ruled out. Inflammatory, autoimmune, and any other condition affecting homeostasis were ruled out by either physical examination or patient history. None of the subjects were smokers and none consumed alcohol.
PCOS has been defined according to the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine PCOS consensus workshop. 15 By this definition, all patients had at least two of the three following criteria: (1) chronic anovulation, (2) clinical and/or biochemical evidence of androgen excess, and (3) polycysticappearing ovaries observed on transvaginal ultrasound scanning. Patients with Cushing's syndrome, hyperprolactinemia, diabetes mellitus, thyroid disease, adrenal hyperplasia and androgen-secreting tumors, or other endocrinopathies were excluded from the study. Patients with adrenal hyperplasia were excluded if adrenocorticotrophic hormone (ACTH)-stimulated 17-hydroxyprogesterone levels were less than 10 ng/mL, 16 and if ACTH-stimulated 11-deoxycortisol levels were less than 21 ng/mL (3 times the 95th percentile 17 of a historical control group of 60 healthy female controls).
Venepuncture was performed on the 10th day of the menstrual cycle following overnight fasting. Withdrawn blood was placed in a container with trisodium citrate (3.8 g/dL) in a proportion of 9:1. The citrated blood was centrifuged at 3500 rpm for 10 minutes at room temperature, and then plasma was collected and frozen at À80 C using liquid nitrogen until testing. Before the final test, the plasma was thawed in a water basin for 15 minutes at a temperature of 37 C. EDTA-anticoagulant samples were used for DNA analysis, and genomic DNA was prepared from blood samples according to standard methods.
Hormonal, serologic, and genetic assays
Hormonally related assays included serum folliclestimulating hormone (FSH), luteinizing hormone (LH), total testosterone, dehydroepiandrosterone sulfate (DHEAS), homocysteine (Hcy), fasting blood sugar (FBS), and fasting insulin. Insulin sensitivity was assessed by the Quantitative Insulin Sensitivity Check Index (QUICKI), defined as 1/[log(-fasting insulin) þ log(fasting glucose)]. 18 Participants were diagnosed as having insulin resistance when the ratio of fasting glucose to fasting insulin was less than 4.5. 19 All the hormonal assays were performed at the Endocrinology and Metabolism Research Center of Nemazee Hospital. Serum FSH (FSH-IRMA, KIP0264; Biosource, Nivelles, Belgium), LH (LH-IRMA CT, REF KP7CT; Radim, Rome, Italy), and DHEAS (DHEA-S-IRMA, KIP0481; Biosource) were measured by immunoradiometric assay. Serum testosterone levels were measured with radioimmunoassay (ESTO-RIA-CT, KIP1709; Biosource). The total fasting Hcy plasma concentration was determined using an enzyme conversion immunoassay kit (Axis-Shield, Dundee, UK). The intra-assay and interassay coefficients of variation were <6% for all assays performed.
All the serologic and genetic assays were performed at the Hematology Research Center of Dastgheib Hospital. Chromogenic assay was used to determine the functional capacity of antithrombin III (HemosIL, Lot 574094; Lexington, MA, USA) and protein C activity (HemosIL, Lot 185659), and total protein S was measured using a protein S clotting assay kit (HemosIL, Lot 285835). At that time, PAI-Fx was also measured. Before the last test for activated protein C resistance was undertaken, plasma was initially mixed with factor V-deficient plasma, and then the activated partial thromboplastin time was measured in response to activated protein C and also in the absence of this agent. A Pro APC kit (HemosIL, Lot N1175277) was used for this purpose, and the APC ratio (APCR) was calculated as the ratio of the clotting times obtained in the presence and absence of activated protein C. Values less than 1.9 were considered to indicate resistance to activated protein C. The clotting assays were performed on an IL instrument (Beckman/Instrumentation Laboratory ACL 9000 -Coagulation Analyzer; MYCO Instrumentation, Inc.; Renton, Washington, USA).
Factor V Leiden analysis
A 287-bp fragment of the factor V gene containing the base pair 1691G/A was amplified using the polymerase chain reaction (PCR). 20 Digestion of the PCR products containing the wild-type, heterozygous, and homozygous alleles with the restriction enzyme MnlI resulted in 37-, 93-, and 157-bp; 157-, 130-, 93-, and 37-bp; and 157-and 130-bp fragments, respectively.
Prothrombin G20210A analysis
A 345-bp fragment of the prothrombin gene containing the base pair 20210G/A was amplified using PCR. 9 Digestion of the PCR products containing the wild-type, heterozygous, and homozygous alleles with the restriction enzyme HindIII resulted in 345-bp; 345-, 322-, and 23-bp; and 322-and 23-bp fragments, respectively
MTHFR analysis
A 198-bp fragment of the MTHFR gene containing base pair 677C/T was amplified using PCR. 21 Digestion of the PCR products containing the wild-type, heterozygous, and homozygous alleles with the restriction enzyme HinfI resulted in 345-bp; 345-, 322-, and 23-bp; and 322-and 23-bp fragments, respectively.
Statistical analysis
The Statistical Package for the Social Sciences, SPSS for Windows, version 15.0 (SPSS, Chicago, IL, USA) was used for data analysis. It was estimated that a sample size of at least 53 individuals per group was needed to detect a significant difference, with a power of 0.8 and an a risk of 0.05. We decided to include 60 subjects per group in order to compensate for nonevaluable patients. Overall differences among group means were compared using one-way analysis of variance (ANOVA), and comparisons between groups were performed by pairwise comparison within the ANOVA model. The Bonferroni test was used as a post hoc test with ANOVA. Categorical variables were analyzed using the c 2 or Fisher's exact tests where applicable. Data are reported as mean AE standard deviation and percentage where appropriate. A two-sided p value <0.05 was considered statistically significant.
Results
Overall, 240 individuals in four study groups were included. Table 1 compares 
and fasting insulin ( p ¼ 0.015), as well as lower insulin sensitivity measured by QUICKI ( p ¼ 0.024), compared to Group 3. Levels of PAI-Fx were also significantly higher in Group 1 than in the other groups ( p ¼ 0.001, p ¼ 0.008, and p < 0.001, respectively). In the same way, PAI-Fx was significantly higher in Group 2 than in Group 4 ( p ¼ 0.018). However, there was no significant difference between Group 2 and Group 4 regarding other metabolic and hormonal parameters (Table 1) . Table 2 demonstrates the mean values for activated protein proportions and APCR. There were no significant differences between study groups regarding activated protein C, protein S, and antithrombin III. However, patients in Group 1 had significantly higher levels of APCR than those in Groups 3 and 4 ( p ¼ 0.009 and p ¼ 0.017, respectively). This finding was also consistent with Group 2 ( p ¼ 0.008 and p ¼ 0.016, respectively). Table 3 shows the distribution of factor V Leiden, prothrombin G20210A, and MTHFR mutations in the four study groups. The prevalence of homozygous factor V Leiden was found to be significantly higher in Group 1 than in Group 3 [odds ratio (OR) 5.8, 95% confidence interval (CI) 0.73e11.6; p ¼ 0.001] or in Group 4 (OR 5.8, 95% CI 0.0.73e11.6; p ¼ 0.001). These findings were also consistent in Group 2 compared to Group 3 (OR 7.25, 95% CI 1.23e14.7; p < 0.001) and in Group 4 (OR 7.25, 95% CI 1.23e14.7; p < 0.001). Heterozygosity of factor V Leiden was also higher in Group 1 than in Group 4 (OR 3.85, 95% CI 0.34e8.1; p ¼ 0.022). It was also higher in Group 2 than in Group 3 (OR 3.763, 95% CI 0.26e6.94; p ¼ 0.001) and Group 4 (OR 5.21, 95% CI 0.94e10.6; p < 0.001). The prevalence of prothrombin G20210A and MTHFR was not found to be significantly different between the four study groups. Neither homozygosity nor heterozygosity of these two genes increased the risk of RPL in the four study groups. The risk of heterozygosity of MTHFR was 1.5-fold higher in Group 1 compared to Group 3, although this was not significant (OR 1.5, 95% CI 0.24e7.58; p ¼ 0.342).
Discussion
Several previous studies have demonstrated the role of both inherited and acquired thrombophilia in RPL. 7, 11, 12 These disorders increase the risk of thrombosis, and thus increase the risk for RPL. 11, 12 Previous studies have also demonstrated that the risk of miscarriage and RPL is significantly higher among patients with PCOS. 3, 4, 13, 14 In other words, it seems that patients with PCOS have an increased risk for both abortion and RPL. Some previous studies have examined this issue. 14, 22, 23 However, the power of this study lies in its four-group design, which can shed light on some of the more difficult components of this subject.
In this study, we tried to investigate the role of hyperandrogenemia, insulin resistance, and hyperhomocysteinemia as well as inherited and acquired thrombophilias in patients with PCOS who had RPL. We found that patients with PCOS and RPL had higher testosterone, DHEAS, and Hcy levels than patients without PCOS but with RPL. RPL in those patients with PCOS was also associated with hypofibrinolysis (measured by PAI-Fx) and decreased insulin sensitivity (measured by QUICKI). We also observed higher levels of Hcy in patients with RPL than in healthy individuals.
Some previous studies have investigated the role of hyperandrogenemia and insulin resistance in the pathogenesis of RPL in PCOS patients. 22 , 24 Tsanadis et al 24 demonstrated that patients with both PCOS and RPL had higher levels of testosterone, estradiol, sex hormone binding globulin, prolactin, and FSH, and lower levels of LH, compared to those without PCOS. However, the level of DHEAS did not differ between the two groups. Taking all of these factors into consideration, it can be concluded that hyperandrogenemia is associated with RPL in patients with PCOS.
We further showed that fasting insulin level and FBS were also higher in those with PCOS and RPL compared to those without RPL, consistent with the results reported by Tsanadis et al. 24 Insulin sensitivity was also significantly lower in these patients. By contrast, Glueck et al 25, 26 showed that administering metformin during pregnancy improves the pregnancy outcomes of patients with PCOS. These findings indicate that a combination of insulin resistance and hyperandrogenemia is responsible for poor pregnancy outcome in those with PCOS. As metformin reduces insulin resistance as well as hyperandrogenemia 27 in patients with PCOS, it can improve pregnancy outcome, as has been shown in previous studies. 5, 26 We found higher levels of Hcy in those with PCOS and RPL compared to those PCOS patients without RPL, suggesting a role for Hcy in the pathogenesis of RPL in patients with PCOS. Balasa et al 28 demonstrated that patients with mutations in MTHFR have higher plasma levels of Hcy. However, MTHFR mutations are responsible for inherited thrombophilia and RPL.
In this study, we showed that the risk of heterozygosity of MTHFR was 1.5-fold higher in those patients with PCOS and RPL compared to the group with PCOS, although this was not significant. However, more individuals were homozygous and heterozygous for MTHFR (6 patients) among these patients compared to the PCOS group (3 patients), and thus the prevalence of mutant allele T was higher (19.9% vs. 8.3%). Consequently, higher levels of Hcy in these patients may be due to a higher prevalence of MTHFR mutations in these groups of patients. Hyperinsulinemia influences Hcy metabolism through different mechanisms, including effects on glomerular filtration or an influence on the activity of key enzymes in Hcy metabolism. 29 Hcy can directly damage endothelial cells, impairing the release of nitric oxide and leading to a net increase in the production of superoxide. Thus, hyperhomocysteinemia can also be secondary to insulin resistance and arise as a result of the metabolic changes of PCOS itself.
We also observed hypofibrinolysis (measured by PAI-Fx) in patients with PCOS and RPL compared to those without RPL, with PCOS incidence rates consistent with those of previous studies. 22, 23 PAI-Fx rises with increasing levels of serum insulin and decreases when insulin is reduced by metformin. 23, 25 Hypofibrinolysis, associated with the 4G/4G polymorphism of the PAI-1 gene, 30 is associated with poor pregnancy outcome as well as second and third trimester complications. High levels of PAI-Fx (reflecting the product of the PAI-1 gene) are related to spontaneous abortion, and PCOS is associated with insulin-induced high PAI-Fx levels. 5, 6 Our study revealed a higher proportion of APCR in patients with RPL with and without PCOS compared to other groups. However, we did not find any association between proteins C and S and antithrombin III and RPL in any of the study groups, which is consistent with findings from previous studies. 22, 24 Proteins C and S are plasma vitamin K-dependent proteins, while antithrombin III is a vitamin K-independent plasma protein; all these proteins are synthesized by the liver. Activated protein C binds protein S and inactivates coagulation factors Va and VIIIa, limiting further coagulation. Protein C and protein S deficiencies will lead to inadequate degradation of factors Va and VIIIa and progression of the hypercoagulatory status. 31 As activated protein C resistance is associated with factor V Leiden, higher proportions of APCR in the PCOS with RPL group can be explained by the higher prevalence of factor V Leiden mutations in this group.
Gene analysis revealed that factor V Leiden mutations are associated with an increased risk of RPL in patients with and without PCOS. Similarly, Behjati et al 32 showed that the frequency of factor V Leiden mutations in patients with infertility (30.6%) or recurrent spontaneous abortion (20.0%) was significantly higher than that of the control group. Contrary to our findings are results from Tsanadis et al, 24 who found no difference between patients with and without PCOS regarding factor V Leiden mutations. However, we failed to find an association between prothrombin G20210A and MTHFR mutations and RPL in both patients with and without PCOS. However, we demonstrated that the risk of MTHFR heterozygosity increased 1.5-fold in the PCOS with RPL group, although not significantly. These findings are consistent with those of previous studies. 22, 24 We did not evaluate other previously mentioned mutations, including factor V A1299H (A4070G) and MTHFR A1298C, which is thought to be associated with RPL in patients with PCOS; this is a limitation of our study.
In summary, patients with PCOS who have RPL have increased levels of serum testosterone, DHEAS, Hcy, insulin, and PAI-Fx, and decreased insulin sensitivity. They also have higher proportions of APCR and a higher prevalence of factor V Leiden mutations compared to PCOS patients without RPL. As discussed above, hyperinsulinemia and insulin resistance is the key step in the pathogenesis of RPL in patients with PCOS. Hyperinsulinemia not only induces hyperandrogenemia in these patients, but also induces hypofibrinolysis (by increasing serum levels of PAI-Fx) and hyperhomocysteinemia; in turn, all of these increase the risk of RPL. However, inherited mutations of factor V Leiden and MTHFR cause APCR and hyperhomocysteinemia, and thus increase the risk for RPL. A combination of these mechanisms can explain the higher prevalence of RPL in patients with PCOS.
In conclusion, hyperinsulinemia, hyperandrogenemia, hypofibrinolysis, and hyperhomocysteinemia as well as APCR and factor V Leiden mutations are associated with RPL in patients with PCOS.
